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Background. Glycogen storage disease type II or
Pompe disease is a neuromuscular disorder caused by
deficiency of lysosomal acid a- glucosidase. Classic
infantile Pompe disease results in massive left ventric-
ular (LV) hypertrophy and failure. Although Pompe
disease is often included in the differential diagnosis
of LV hypertrophy the true frequency of cardiac
involvement in adults with Pompe disease is not
known.
Methods. Forty-six consecutive adult patients (mean
age 48 ± 12, 22 men) with Pompe disease were
included. Each patient underwent a clinical examina-
tion, electrocardiography, and rest and low-dose dobu-
tamine (in 20 patients) two-dimensional
echocardiography including contrast and tissue
Doppler imaging.
Results. All patients had limited exercise tolerance; a
rollator walking aid was used in seven patients (15%),
a wheelchair in 13 patients (28%), and assisted venti-
lation in 14 patients (30%). Prior to this study, one
patient was known with permanent atrial fibrillation,
His-bundle ablation and a VVI pacemaker and
another patient was known with fluid retention. The
first patient had increased LV end-diastolic diameter,
impaired LV ejection fraction, low systolic mitral
annular velocities and diastolic dysfunction grade II.
The patient with fluid retention was wheelchair bound
and dependent on 24-h assisted ventilation and
showed right ventricular and LV hypertrophy (septum
16 mm, posterior wall 15 mm). LV hypertrophy was
not seen in any of the other patients. One woman of
advanced age had isolated low systolic mitral annular
velocities. Mean global systolic LV function, includ-
ing contractile reserve, was not decreased in patients
with Pompe disease. Eight patients (17%) had mild
diastolic dysfunction grade I, related to hypertension
in four and advanced age in seven.
Conclusions. In adult patients with Pompe disease
without objective signs of cardiac affection by 12-
leads electrocardiography or physical examination,
echocardiographic screening for LV hypertrophy
seems not effective.
Keywords: cardiomyopathy, echocardiography, glyco-
gen storage disease.
Introduction
Glycogen storage disease type II (GSD II), or Pompe
disease, is an autosomal recessive disorder caused by
inherited deficiency of a-1,4-glucosidase (acid mal-
tase), a lysosomal enzyme that hydrolyses glycogen
into glucose [1]. The disease has an incidence of
approximately 1 : 40 000 births and affects various
body tissues, especially muscle tissue [2, 3]. The
genetic abnormality is in the GAA gene, traced to the
long arm of chromosome 17 [2, 3]. Glycogen is pres-
ent in excessive amounts in Pompe disease, both
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within lysosomes and free in the cytoplasm [4].
Patients usually die in the first years of life from car-
dio-respiratory failure due to massive left ventricular
(LV) hypertrophy [5]. A partial deficiency of a-gluco-
sidase activity leads to milder, late-onset phenotypes
Pompe disease [6, 7]. Adult patients with Pompe dis-
ease generally have a relatively slow disease progres-
sion and usually die because of respiratory failure [6,
7]. Still, glycogen storage diseases are often men-
tioned in the differential diagnosis of LV hypertrophy
in adults [5]. The present study for the first time
sought to assess in detail cardiac abnormalities with
emphasize on LV dysfunction and hypertrophy in
adult patients with Pompe disease.
Methods
Study population
In collaboration with our department of neurology, a
standard program was initiated to prospectively inves-
tigate cardiac function with a 12-lead electrocardio-
gram and detailed echocardiography in a large
(n = 46) cohort of adult patients with Pompe disease
(first symptoms reported by the patients and diagnosis
after the age of 18 years). The diagnosis Pompe dis-
ease was confirmed in all patients through mutation
analysis (compound heterozygote with the common
c.-32-13T>G mutation on one allele) and measure-
ment of decreased acid a-glucosidase activity in leu-
kocytes or fibroblasts. Mean age of the patients was
48 ± 12 years (range 25–71 years) and 22 patients
(48%) were male. All patients gave informed consent
before participating in the study and the institutional
review board approved the study.
Clinical studies
In all patients respiratory function and exercise toler-
ance was semi-quantitatively estimated. Respiratory
function was graded as 0 = normal, 1 = partial depen-
dence on assisted ventilation, and 2 = 24-h depen-
dence on assisted ventilation. Exercise tolerance was
graded as 0 = normal, 1 = limited, 2 = dependence on
a rollator walking aid, 3 = dependence on a wheel-
chair.
Two-dimensional echocardiography
Echocardiographic studies were performed with a
Sonos 7500 ultrasound system (Philips, Best, The
Netherlands) by a single, experienced sonographer
(WBV). The acquired data were digitally stored and
subsequently analysed by two observers (MLG,
OIIS) who were blinded for the clinical data. All
echocardiographic measurements were averaged from
three beats. From the second harmonic M-mode
recordings the following data were acquired: left
atrial dimension (normal value £40 mm), LV end-dia-
stolic septal and posterior wall thickness, and LV
end-diastolic dimension (normal value £56 mm). LV
volume and septal thickness assessment was opti-
mized with SonoVue contrast [8]. LV ejection frac-
tion was calculated from LV volumes by the
modified biplane Simpson rule in accordance with
guidelines (normal value ‡50%) [9]. LV mass was
calculated using the modified Devereux formula and
indexed by body surface area (normal values in men:
£150 g m)2, in women £120 g m)2) [10]. From the
mitral-inflow pattern peak early (E) and late (A) fill-
ing velocities, E ⁄A ratio, E-velocity deceleration time
and duration of A-velocity were measured. Pulmo-
nary vein systolic and diastolic flow and atrial rever-
sal (velocity and duration) were also measured.
Diastolic function was subsequently graded 1 to 4
according to an accepted protocol [11].
Tissue Doppler imaging
Tissue Doppler was applied end-expiratory in the
pulsed-wave Doppler mode at the level of the infero-
septal and anterolateral side of the mitral annulus
from an apical 4-chamber view. To acquire the highest
wall tissue velocities, the angle between the Doppler
beam and the longitudinal motion of the investigated
structure was adjusted to a minimal level. The tissue
pulsed-wave Doppler velocity range was adjusted to
obtain an appropriate scale. LV systolic (LV-Sm), and
early diastolic (Em) peak velocities were averaged
from three samples. Subsequently, mean (calculated
from the inferoseptal and anterolateral wall) Sm, mean
Em and the dimensionless parameter E ⁄mean Em were
calculated.
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Normal values for mean LV-Sm were calculated from
46 for age and gender matched healthy volunteers
with normal left atrial and LV dimensions and LV
function as described before [12]. The normal lower
cut-off value for mean LV-Sm was 7.6 cm s
)1. The
(volunteers and literature derived) normal higher cut-
off value for E ⁄Em, indicating a most likely low end-
diastolic LV pressure, was set to 9 [13, 14].
Low-dose dobutamine stress echocardiography
In the first 20 patients and in healthy volunteers
(matched for age and gender) a low-dose dobutamine
(10 lg kg)1 min)1) contrast stress echocardiogram
was performed according to standard recommenda-
tions [15] to assess increases in stroke volume and
LV-Sm (contractile reserve).
Results
Clinical presentation
All patients had limited exercise tolerance, a rollator
walking aid was used in seven patients (15%), and a
wheelchair was used in 13 patients (28%). Assisted
ventilation was used in 14 patients (30%), of whom
one was 24-h dependent on assisted ventilation. Prior
to this study, a 67-year-old male (patient no. 4) was
known with permanent atrial fibrillation treated with
His-bundle ablation and a VVI pacemaker. One 57-
year-old male (no. 24) was known with fluid retention
treated with furosemide and spironolacton.
Rhythm and conduction abnormalities
Apart from the previously mentioned patient no. 4
known with VVI pacing, conduction abnormalities
were present in three other patients (7%). The previ-
ously mentioned patient no. 24 known with fluid
retention had right bundle branch block with left ante-
rior hemi-block, patient no. 21 (a 50-year-old female)
had left bundle branch block, and patient no. 27 (a
45-year-old male) had isolated left anterior hemi-
block. One patient (no. 23, a 35-year-old female)
without palpitations showed an atrial rhythm (positive
P-waves in leads I and II, flat P-wave in lead aVF)
with a short PR-interval of 114 ms without evidence
of a d-wave.
Left atrial and LV dimensions
The 67-year-old male (patient no. 4) known with per-
manent atrial fibrillation, His-bundle ablation and a
VVI pacemaker had an increased LV end-diastolic
diameter. The 57-year-old wheelchair bound male
(patient no. 24) dependent on 24-h assisted ventilation
and known with fluid retention had right ventricular
and LV hypertrophy (septum 16 mm, posterior wall
15 mm) but due to relatively small LV size, LV mass
was still within the normal range. Minor nonspecific
septal sparkling was present in a 68-year-old woman
(patient no. 35) with normal left atrial and LV dimen-
sions and normal LV mass.
LV systolic function
Overt systolic LV dysfunction, evidenced by a 48% LV
ejection fraction and low systolic TDI values, was pres-
ent in the previously mentioned 67-year-old male
(patient no. 4) known with permanent atrial fibrillation,
His-bundle ablation and a VVI pacemaker. The previ-
ously described 68-year-old woman (patient no. 35)
with minor aspecific septal sparkling, normal left atrial
and LV dimensions and normal LV mass had isolated
low systolic mitral annular velocities. All other patients
had normal parameters of LV systolic function (see
Table 1). Stroke volume increase during low-dose do-
butamine in Pompe patients and healthy volunteers was
not different (95 ± 25 to 109 ± 32 mL, 18% increase
vs. 81 ± 19 to 96 ± 27 mL, 19% increase). Also, the
increase in mean LV-Sm was not different in Pompe
patients and healthy volunteers (9.7 ± 1.2 to
12.7 ± 1.9 cm s)1, 31% increase vs. 9.1 ± 1.4 to
12.4 ± 2.2 cm s)1, 36% increase).
Diastolic function
Nine patients had mild diastolic dysfunction. Grade I
dysfunction without evidence for increased LV filling
pressures was present in eight patients (nos 8, 18, 19,
34, 35, 42, 44 and 46) and grade II dysfunction was
present in the previously mentioned 67-year-old male
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Table 1 Demographic and clinical characteristics of the patients with Pompe disease
Pt Age Sex DM ⁄HT
Symptom
onset
age
Exercise
tolerancea Ventilationb
LA
size
(mm)
LV-EDD
(mm)
LV mass
index
(g m)2)
LV-EF
(%)
LV-Sm
(cm s)1)
Diastolic
dysfunction
grade E ⁄Em
1 25 F ) ⁄) 18 1 0 32 38 69 60 8.5 5.6
2 26 F ) ⁄) 18 2 0 29 41 58 64 8.1 7.8
3 37 M ) ⁄) 18 1 1 39 46 64 53 11.0 7.0
4 67 M ) ⁄) 20 2 0 38 58 134 48 5.1 II 13.3
5 37 F ) ⁄) 22 1 1 30 49 70 52 8.1 8.6
6 30 M ) ⁄) 23 1 0 33 49 85 84 12.9 6.6
7 38 F ) ⁄) 23 3 0 30 46 60 82 10.7 3.9
8 60 F ) ⁄) 23 3 0 28 40 64 66 8.3 I 8.7
9 30 M ) ⁄) 23 1 0 40 55 81 54 11.0 3.6
10 39 F ) ⁄) 24 1 0 34 43 63 52 9.9 7.6
11 34 F ) ⁄) 24 1 0 35 51 83 68 8.7 7.1
12 36 F + ⁄ + 26 1 1 33 49 77 68 8.3 6.5
13 47 M ) ⁄ + 26 2 1 31 50 97 60 9.4 4.4
14 50 F ) ⁄) 28 3 0 34 43 72 70 9.1 7.9
15 49 M ) ⁄ + 29 1 0 32 55 87 69 9.7 4.0
16 63 M ) ⁄ + 29 3 1 31 52 78 74 10.1 6.2
17 37 M ) ⁄) 29 1 0 34 53 91 69 10.0 5.7
18 41 M ) ⁄ + 30 1 1 28 52 68 70 9.5 I 5.4
19 67 M ) ⁄) 30 3 1 32 36 47 62 10.8 I 5.7
20 65 M ) ⁄) 31 3 0 39 51 80 74 9.1 5.6
21 50 F ) ⁄) 31 3 0 29 46 83 69 10.6 4.0
22 37 M ) ⁄) 32 1 0 26 53 102 64 8.6 5.1
23 34 F ) ⁄) 33 1 0 28 45 95 57 9.9 4.2
24 57 M ) ⁄) 33 3 2 32 39 122 67 NA NA NA
25 38 M ) ⁄) 33 1 0 30 47 89 59 10.2 6.4
26 43 F + ⁄) 35 3 0 28 50 84 68 10.6 6.1
27 45 M ) ⁄) 35 1 0 35 46 82 69 11.2 4.6
28 40 F ) ⁄) 36 1 0 30 51 82 58 8.3 6.6
29 51 F ) ⁄ + 36 3 0 34 44 70 61 9.2 7.4
30 41 M ) ⁄) 36 2 0 30 41 66 64 10.8 6.5
31 42 F ) ⁄) 36 1 0 31 51 75 53 7.6 6.1
32 41 F ) ⁄) 37 1 0 35 42 72 63 11.7 4.7
33 53 M ) ⁄) 38 2 0 40 48 88 52 8.6 8.0
34 55 M ) ⁄ + 39 1 1 31 50 90 69 8.3 I 3.7
35 68 F ) ⁄) 40 3 1 28 46 71 78 6.3 I 5.7
36 48 F ) ⁄ + 40 1 0 32 41 68 74 10.4 4.9
37 46 M ) ⁄) 40 1 0 30 52 64 69 8.1 6.3
38 57 F ) ⁄) 41 2 1 28 53 92 71 9.0 5.5
39 50 F ) ⁄) 43 1 0 28 46 78 68 8.4 7.1
40 47 F ) ⁄) 43 1 0 30 43 78 58 8.2 5.0
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(patient no. 4) with permanent atrial fibrillation, His-
bundle ablation and a VVI pacemaker. Unfortunately,
tissue Doppler measurements could not be obtained
reliably due to angulation problems in the previously
described patient no. 24 with right ventricular and LV
hypertrophy.
Discussion
This is the first study in which cardiac involvement in
a large, nonselected series of adult patients with
Pompe disease was studied in detail. The incidence of
atrio-ventricular conduction abnormalities and LV
hypertrophy was markedly lower than that reported in
the literature on classic infantile Pompe disease [16].
In our series of 46 adult patients with Pompe disease
only one wheelchair-bound patient dependent on
assisted ventilation and known with fluid retention
showed right ventricular and LV hypertrophy and one
other patient had a short PR-interval.
Electrocardiographic abnormalities
A short PR interval without evidence of a d-wave in
the presence of an atrial rhythm was seen in one
patient without palpitations. In previous reports in
classic infantile patients, high incidences of pre-exci-
tation, defined as a short PR-interval, were reported
[17, 18]. Also, Wolf-Parkinson-White syndrome has
been reported to occur in Pompe disease [19]. The
presumed electrophysiological basis of accelerated
atrio-ventricular conduction in Pompe disease may be
related to the insulator effect of glycogen in atrio-ven-
tricular conduction tissue [20]. Even when we
consider our patient to really have abnormal atrio-
ventricular conduction (this may also be physiological
in the presence of a low atrial rhythm), a coincidental
occurrence of pre-excitation and Pompe disease in this
single patient cannot be ruled out since the prevalence
of pre-excitation in the general population may be as
high as 3% [21]. In addition, the prevalence of con-
duction abnormalities in the bundle branches found in
our study (7%) is not higher than that amongst the
general population [22, 23].
Echocardiographic abnormalities
It is well known that in neonates with Pompe disease
glycogen accumulation can result in massive LV
hypertrophy [5]. In our study, only a 57-year-old
wheelchair bound male dependent on assisted ventila-
tion and known with fluid retention had right ventric-
ular and LV hypertrophy. It is important to realize
that LV septal thickness assessment in our study was
optimized with SonoVue contrast [8] to reliably
exclude LV hypertrophy. Mean global systolic LV
function, including contractile reserve, was not
decreased in patients with Pompe disease. Minor car-
diac abnormalities (isolated low systolic mitral annu-
lar velocities or mild LV diastolic dysfunction) were
Table 1 (Continued)
Pt Age Sex DM ⁄HT
Symptom
onset
age
Exercise
tolerancea Ventilationb
LA
size
(mm)
LV-EDD
(mm)
LV mass
index
(g m)2)
LV-EF
(%)
LV-Sm
(cm s)1)
Diastolic
dysfunction
grade E ⁄Em
41 52 F ) ⁄) 44 2 0 33 51 72 80 9.5 7.8
42 61 M ) ⁄ + 44 3 1 37 45 71 71 15.5 I 6.8
43 52 M ) ⁄ + 46 1 0 40 50 89 62 9.8 6.4
44 59 M ) ⁄) 47 1 1 38 43 51 51 10.4 I 5.8
45 55 F ) ⁄) 49 1 1 31 40 64 80 9.3 4.8
46 71 F ) ⁄ + 62 3 0 28 45 69 69 10.1 I 4.1
DM, diabetes mellitus; E, early passive mitral inflow; Em, early mitral annular tissue velocity; LA, Left atrium; LV-EDD, LV end-diastolic
diameter; LV-EF, LV ejection fraction; LV-Sm, LV systolic velocities averaged from septal and lateral mitral annulus; HT, Hypertension.
aExercise tolerance: 1 = limited, 2 = (rollator) walking aid, 3 = wheelchair.
bAssisted ventilation: 0 = none, 1 = <24 h respirator, 2 = 24 h assisted ventilation).
Values in bold are abnormalities.
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present in a few patients. The patient with isolated
low systolic mitral annular velocity (no. 35) was of
advanced age. All patients with mild diastolic dys-
function grade I had a history of hypertension (nos
18, 34, 42, 46) or had advanced age (nos 8, 19, 35,
42, 44, 46), conditions well known to be related to
lower systolic mitral annular velocities and mild dia-
stolic dysfunction [11, 24, 25]. Despite the inclusion
of Pompe disease in the differential diagnosis of LV
hypertrophy in cardiac textbooks our study results
seem not to justify this for adults with Pompe disease.
Recently, Arad et al. found in none of the 75 adult
patients with unexplained LV hypertrophy evidence
for Pompe disease [5]. Since in our study even in
patients with severe skeletal or respiratory muscle
affection none of the aforementioned echocardio-
graphic methods found any alterations suggesting LV
hypertrophy it seems certainly not indicated to screen
patients with normal skeletal muscle function and LV
hypertrophy for Pompe disease.
Genetic basis of Pompe
Pompe disease is an autosomal recessive disorder
resulting from abnormalities in the GAA gene, traced
to the long arm of chromosome 17 [3, 26]. All our
patients had the c.-32-13T>G mutation on one allele
which is the most frequent mutation seen in patients
with Pompe [27]. In infants with the classic infantile
phenotype, severe myocardial hypertrophy obliterates
the LV lumen and causes LV outflow obstruction in
virtually all patients, resulting in fatal cardiac failure
[28, 29]. The impressive difference in the prevalence
and severity of cardiac involvement in infants com-
pared to adults seen in this study is most likely due to
the higher amount of residual a-glucosidase activity
in adults [30]. A low level of enzyme activity seems
sufficient to prevent intra-lysosomal accumulation of
glycogen in cardiomyocytes. In addition, there are dif-
ferences in storage capacity and metabolism of heart
and skeletal muscle [31].
Conclusions
Apart from abnormalities in a patient known with per-
manent atrial fibrillation, His-bundle ablation and a
VVI pacemaker and a single patient with cardiac
hypertrophy, none of our adult patients with Pompe
disease showed major cardiac abnormalities. All
minor cardiac abnormalities could be explained by a
history of longstanding hypertension and ⁄or advanced
age. Because, in adult patients with Pompe disease
without objective signs of cardiac affection by 12-
leads electrocardiography or physical examination,
none of the aforementioned echocardiographic meth-
ods found any alterations suggesting LV hypertrophy
or overt LV dysfunction, echocardiographic screening
seems not effective.
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